SUGI HOLDINGS CO.LTD.

Company Overview

SUGI operates Japanese drugstores and dispensing pharmacies, concentrated in the Kanto, Chubu and Kansai regions but increasingly nationwide after acquisitions. At February 2026 it had 2,321 locations, including 1,834 drugstores and 454 stand-alone pharmacies. Consumers pay for medicines, cosmetics, food and household goods; patients and public insurers pay for prescriptions. The investment outcome depends less on near-term sales growth than on whether SUGI can preserve its roughly 5% operating margin while directing much larger amounts of capital into new stores and acquisitions. The core business remains healthy, but the stock offers only a modest margin of safety once abnormal cash flow and dilution are removed.

How the Company Makes Money

Merchandise remains the largest profit pool. Fiscal 2026 merchandise sales were ¥685.2 billion, or 68% of revenue, versus ¥307.3 billion from dispensing. Merchandise gross margin reached 29.1%, implying roughly 62% of consolidated gross profit originated in retail goods; dispensing contributed approximately one-third at a higher gross margin but with greater pharmacist labor requirements. Customers choose SUGI for convenient locations, broad daily-needs assortments, coupons, points and access to an attached pharmacy. Patients also value proximity to medical providers, prescription-app convenience and the ability to handle specialty or home-care prescriptions.

The defensible advantage is local density rather than exclusive products. A dense store network lowers distribution costs, improves brand familiarity and supports clinic relationships. SUGI’s 25.5 million point members, 15.7 million app downloads and 64.8% app-member share of merchandise sales allow more targeted promotions than undifferentiated discounting. Scale also improves purchasing terms and supports private-label products. These advantages are real but replicable: large competitors possess similar capital, customer data and supplier access, while prescription prices and dispensing fees remain government-controlled.

The main constraint is the cost of operating physical stores. Fiscal 2026 personnel expense was ¥137.1 billion, 13.6% of sales; rent was ¥49.0 billion and total selling and administrative expense consumed 27.0% of revenue. Operating margin was therefore only 4.8%. SUGI plans 572 drugstore openings and 1,210 renovations over five years while assuming annual wage inflation of 5%. Growth creates value only if same-store sales, private-label mix and pharmacy productivity outrun wages, rent, construction costs and the capital tied up in immature stores.

Why the Stock Fell

From the verified January 21, 2026 high of ¥1,991 to the September 30 close of ¥1,253, the split-adjusted share price fell 37%. The largest apparent deterioration was not operational. Fiscal 2026 net income rose 75% to ¥45.0 billion because income-tax expense fell to only ¥0.2 billion after tax adjustments. Management then guided fiscal 2027 net income down 27% to ¥32.8 billion, even while forecasting operating profit up 11% to ¥54.0 billion. The share price therefore absorbed the reversal of a tax benefit that never represented sustainable earning power.

The more substantive change is capital allocation. In April, management introduced a five-year plan requiring ¥240 billion of investment, including ¥100 billion for systems and M&A plus capacity for another ¥100 billion of large acquisitions, partly financed with debt. In July, SUGI issued 5.082 million pre-split shares to GIC, raising approximately ¥16.0 billion net and diluting existing holders by about 2.8%. On September 1, Seki Yakuhin became a consolidated subsidiary; its latest disclosed operating margin was 3.2%, below SUGI’s 4.8%. The market is reasonably questioning whether faster growth will improve per-share cash flow.

Observed trading has not shown a collapse in the stores. Fiscal 2027 first-quarter revenue rose 10.1% and operating profit 10.9%, with operating margin slightly higher year on year. August existing-store sales increased 2.3% in merchandise and 9.7% in dispensing. The evidence supports slower retail momentum and rising financing costs, not structural customer loss.

What the Market Is Assuming

The supplied September 30 market capitalization of ¥453.518 billion at ¥1,253 corresponds to 361.946 million shares and does not incorporate the July GIC issuance. After the allotment and September stock split, approximately 372.110 million treasury-excluded shares were outstanding, producing an updated equity value of about ¥466.3 billion at the same price. The model uses this diluted count. The new cash is not added as excess value because management has earmarked it for stores, technology and M&A.

Conditional reverse valuation: at an 8% required equity return, ¥466.3 billion requires sustainable annual distributable cash of ¥37.3 billion with no growth, or ¥28.0 billion with 2% perpetual growth. Fiscal 2027 guidance implies approximately ¥24.0 billion after full planned capital expenditure: ¥32.8 billion net income plus ¥23.4 billion depreciation and goodwill amortization, less ¥32.2 billion capex, before working-capital movements. The price therefore assumes that part of capex is genuinely discretionary growth investment and that it eventually raises annual cash available to shareholders above roughly ¥28 billion.

Temporary or Structural?

Mixed, but predominantly TIME in reported earnings and potentially ESSENCE in capital allocation. The forecast decline in net income is mainly the normalization of fiscal 2026’s unusually low tax expense. Revenue, gross profit, prescriptions and operating profit are still advancing. The app, pharmacy network and local store density remain intact, while I&H has reportedly returned from an ordinary loss to profitability after purchasing and head-office functions were integrated.

The balance sheet can endure a disappointing integration period. At February 2026 SUGI reported ¥111.2 billion of cash against approximately ¥94.0 billion of interest-bearing borrowings, ¥290.5 billion of net assets and a 47.3% equity ratio; the subsequent GIC proceeds added liquidity. This is not a survival or refinancing thesis. The risk is that capital survives while returns deteriorate: SUGI can afford mediocre acquisitions that permanently lower per-share earning power.

The strongest contrary evidence is the combination of recurring store impairments, lower-margin Seki operations and an aggressive plan to expand despite wage inflation. Fiscal 2026 impairment losses were ¥5.8 billion, 46 stores closed, and operating cash flow benefited from a ¥31.7 billion increase in trade payables, partly caused by fiscal year-end payment timing. If management must keep spending near ¥30 billion annually merely to maintain competitiveness, the apparent cash-generating advantage largely disappears.

Is the Market Wrong? By How Much?

The supplied owner-earnings figure is ¥71.761 billion, a 15.82% yield and 6.32-year payback on the supplied market capitalization. It is arithmetically consistent with fiscal 2026 operating cash flow of ¥86.779 billion less approximately ¥15.0 billion of narrowly defined capital expenditure. It is not a defensible normalized base. Operating cash flow included the ¥31.7 billion payable increase, while the company’s investor data reported total capital expenditure of ¥25.75 billion when systems and refurbishment were included. The negative ¥12.924 billion NCAV also confirms that this is not an asset-backed cigar butt; the ¥290.474 billion book value and supplied 1.56 times price-to-book ratio depend on profitable continued operation.

The valuation starts with fiscal 2027 guidance and separates maintenance spending from growth spending. No stock-compensation add-back is made, and the post-allotment share count captures dilution.

The bear case assumes Seki’s lower margin, wage inflation and recurring store refurbishment absorb most procurement and digital gains. The base case keeps operating economics near current levels while dispensing mix and modest productivity gains support 2% long-term cash growth. The bull case requires progress toward management’s 5.5% operating-margin target, with I&H and Seki producing real purchasing and labor synergies rather than merely adding revenue.

The evidence supports modest underpricing, not a large valuation error. Current operations justify the price if normalized distributable cash reaches approximately ¥30–33 billion, but the base-case upside is only about 9%. The assumption most threatening that conclusion is maintenance capital: if annual spending near ¥25–30 billion is necessary simply to defend existing sales and systems, value is closer to the bear case. Conversely, successful deployment of the growth budget could make the present price attractive without requiring multiple expansion.

Key Facts, Estimates, and Judgments